Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review

被引:0
作者
Willem Boer
Walter Verbrugghe
Eric Hoste
Rita Jacobs
Philippe G. Jorens
机构
[1] Ziekenhuis Oost Limburg ZOL,Department of Anaesthesiology, Intensive Care Medicine, Emergency Medicine & Pain Medicine
[2] University of Antwerp,Department of Critical Care Medicine, Antwerp University Hospital
[3] Ghent University,Intensive Care Unit, Department of Internal Medicine and Paediatrics, Ghent University Hospital, Ghent, and Research Foundation Flanders (FWO)
[4] University of Antwerp,Department of Critical Care Medicine, Antwerp University Hospital, LEMP
来源
Annals of Intensive Care | / 13卷
关键词
Citrate anticoagulation; Calcium balance; Hormones; Phosphate; Magnesium; Review;
D O I
暂无
中图分类号
学科分类号
摘要
The use of citrate, through reversible binding of calcium, has become the preferred choice for anticoagulation in continuous renal replacement therapy in the critically ill patient. Though generally considered as very efficacious in acute kidney injury, this type of anticoagulation can cause acid–base disorders as well as citrate accumulation and overload, phenomena which have been well described. The purpose of this narrative review is to provide an overview of some other, non-anticoagulation effects of citrate chelation during its use as anticoagulant. We highlight the effects seen on the calcium balance and hormonal status, phosphate and magnesium balance, as well as oxidative stress resulting from these unapparent effects. As most of these data on these non-anticoagulation effects have been obtained in small observational studies, new and larger studies documenting both short- and long-term effects should be undertaken. Subsequent future guidelines for citrate-based continuous renal replacement therapy should take not only the metabolic but also these unapparent effects into account.
引用
收藏
相关论文
共 326 条
[41]  
Selleng S(2013)Phosphate balance in continuous venovenous hemofiltration Am J Kidney Dis 30 1662-815
[42]  
Kindgen-Milles D(2004)Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy Intensive Care Med 359 7-210
[43]  
Ostermann M(2008)Intensity of renal support in critically ill patients with acute kidney injury New Engl J Med 361 1627-232
[44]  
Slowinski T(2009)Intensity of continuous renal-replacement therapy in critically ill patients New Engl J Medicine 75 312-320
[45]  
Balik M(2009)Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children Kidney Int 26 3508-852
[46]  
Zakharchenko M(2011)Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury Nephrol Dial Transpl 55 39-15
[47]  
Otahal M(2011)Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy Acta Anaesth Scand 14 R147-312
[48]  
Hruby J(2010)Treatment of hypophosphatemia in the intensive care unit: a review Crit Care 17 R205-26
[49]  
Polak F(2013)Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury Critical care 28 884.e7-642
[50]  
Rusinova K(2013)Phoxilium vs Hemosol-B0 for continuous renal replacement therapy in acute kidney injury J Crit Care 44 807-22